Patients were randomised ( @:@ ) via a centralised , interactive voice-response system to receive @ mg/kg intravenous ramucirumab plus FOLFIRI or matching placebo plus FOLFIRI every @ weeks until disease progression , unacceptable toxic effects , or death .